Q&A

Developing Life-Saving Medicines Through Cell Culture Technologies

Evonik2

In this expert interview, Dr. Martin Schilling of Evonik Health Care talks to Professor Michael Betenbaugh of Johns Hopkins University about the most exciting advances in cell culture-based production of biological drugs, collaborations between industry and academia, and future trends.

Topics covered include major advances in cell culture, the speed of development for mRNA and cell-culture based COVID-19 vaccines and monoclonal antibodies, the ever-accelerating rate of biological innovation, and an international academic-industrial collaboration initiative, AMBIC (Advanced Mammalian Biomanufacturing Innovation Center).

Dr. Martin Schilling, Director Cell Culture Ingredients at Evonik Health Care, is responsible for Evonik’s product portfolio of high-quality cell culture ingredients that are used to improve biopharma cell culture processes. He also manages Evonik’s innovation program that leverages existing core competencies in biotechnology, chemistry, and formulation development to address other emerging needs within the cell culture industry. Martin has a strong technical background in cell culture and industrial biotechnology and earned his Ph.D. in biochemistry from the Technical University of Munich in Germany in 2008.

VIEW THE Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online